山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (1): 110-113.doi: 10.6040/j.issn.1673-3770.0.2016.328

• 无栏目 • 上一篇    下一篇

玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察

严槟,尹小芳,叶祖科,卢彦,洪剑威   

  1. 广东省佛山市第二人民医院眼科中心, 广东 佛山 528000
  • 收稿日期:2016-07-27 出版日期:2017-02-16 发布日期:2017-02-16
  • 基金资助:
    广东省佛山市科技计划项目(2015122)

Clinical observation on the treatment of BRVO-ME by the combination of laser therapy with Ranibizumab intravitreal injection.

  1. Department of Ophthalmology, Second Peoples Hospital of Foshan, Foshan 528000, Guangdong, China
  • Received:2016-07-27 Online:2017-02-16 Published:2017-02-16

PDF (PC)

584

摘要： 目的 研究视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)患者应用雷珠单抗玻璃体腔注射联合格栅样视网膜激光光凝术(GLP)治疗的临床效果。 方法 选取135例(135眼)BRVO-ME临床资料,随机分为单纯药物组(n=45)、单纯激光组(n=45)、联合治疗组(n=45),单纯药物组仅应用雷珠单抗玻璃体腔注射,单纯激光组仅应用GLP治疗,联合治疗组先予雷珠单抗玻璃体腔注射,间隔1周后应用GLP治疗。 结果 三组治疗3个月后最佳矫正视力(BCVA)水平对比,较治疗前差异有统计学意义(P<0.05),且联合治疗组治疗1、2、3个月后BCVA水平较同期单纯药物组、单纯激光组差异有统计学意义(P<0.05)。三组治疗3个月后黄斑中心凹视网膜厚度(CMT)水平对比,均较治疗前差异有统计学意义(P<0.05),且联合治疗1、2、3个月后CMT水平较同期单纯药物组、单纯激光组差异均有统计学意义(P<0.05)。 结论 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME较单纯药物和单纯激光治疗,降低黄斑中心凹视网膜厚度、改善黄斑水肿、提高视力效果更明显,复发率更低,安全有效。

关键词: 视网膜激光光凝术, 雷珠单抗, 视网膜分支静脉阻塞, 黄斑水肿

Abstract: Objective To explore the clinical efficacy of branch retinal vein occlusion secondary macular edema(BRVO-ME)treated with Ranibizumab intravitreal injection combined with grille laser photocoagulation(GLP). Methods A total of 135(135 eyes)BRVO-ME cases were divided into 3 groups: simple drug group(n=45), simple laser group(n=45), and combined treatment group(n=45). The simple drug group received Ranibizumab intravitreal injection only. The simple laser group received GLP only. The combined treatment group received Ranibizumab intravitreal injection first, and then GLP 1 week after. The best corrected visual acuity(BCVA), central macular thickness(CMT), and intraocular pressure(IOP)of the 3 groups were observed. Results Three months after treatment, BCVA and CMT of all groups were significantly different(P<0.05). The combined treatment group had significantly lower BCVA and CMT than the other 2 groups in postoperative month 1, 2 and 3(P<0.05). During the treatment, no increased IOP was observed(P>0.05). No postoperative infection, vitreous hemorrhage, bacterial endophthalmitis or other adverse reactions occurred. Conclusion Ranibizumab intravitreal injection combined with GLP is safe and effective in the treatment of BRVO-ME, which can reduce the CMT, relieve macular edema, and improve visual acuity.

Key words: Ranibizumab, Grille laser photocoagulation, Branch retinal vein occlusion, Macular edema

中图分类号: 

  • R774.5
[1] 王晓波,吴国基,张雪岩,等. 玻璃体腔注射雷珠单抗联合激光治疗视网膜分支静脉阻塞[J]. 国际眼科杂志,2013,25(12):2452-2455. WANG Xiaobo, WU Guoji, ZHANG Xueyan, et al. Intravitreous injection with ranibizumab combined laser photocoagulation for the treatment of branch retinal vein occlusion[J]. Int Eye Sci, 2013, 25(12):2452-2455.
[2] 吴李鑫,张悦,刘海芸,等. 玻璃体腔注射雷珠单抗联合激光治疗视网膜中央静脉阻塞继发黄斑水肿[J].中国实用眼科杂志,2015,33(9):1004-1007. WU Lixin, ZHANG Yue, LIU Haiyun, et al. Intravitreal ranibizumab combined with grid photocoagulation for macular edema of central retinal vein occlusion[J]. Chin J Pract Ophthalmol, 2015, 33(9):1004-1007.
[3] 叶湘湘,陈中山,丁琴,等. 玻璃体腔注射雷珠单抗与光动力疗法联合玻璃体腔注射雷珠单抗治疗特发性脉络膜新生血管的疗效比较[J]. 中华眼底病杂志,2013,29(4):362-366. YE Xiangxiang, CHEN Zhongshan, DING Qin, et al. Intravitreal ranibizumab injection combined with or without photodynamic therapy for idiopathic choroidal neovascularization: a comparative efficacy study[J]. Chi J Ocul Fund Dis, 2013, 29(4):362-366.
[4] 傅维娜,陈梅珠,王云鹏. 手术前玻璃体腔注射雷珠单抗对增生型糖尿病视网膜病变患眼玻璃体切割手术操作时间及手术后视力的影响[J]. 中华眼底病杂志,2016,32(1):26-30. FU Weina, CHEN Meizhu, WANG Yunpeng. The effect of preoperative intravitreal ranibizumab injection on the operation duration of vitrectomy and postoperative vision for the treatment of proliferative diabetic retinopathy[J]. Chi J Ocul Fund Dis, 2016, 32(1):26-30.
[5] Battaglia Parodi M, Saviano S, Bergamini L, et al. Grid laser treatment of macular edema in macular branch retinal vein occlusion[J]. Doc Ophthalmol, 1999, 97(3-4):427-431.
[6] 吕勇,范琼艳,杨琳,等. 老年白内障手术联合玻璃体腔注射雷珠单抗对糖尿病性黄斑水肿影响[J]. 中国实用眼科杂志,2014,32(5):560-563. LÜ Yong, FAN Qiongyan, YANG Lin, et al. Effect of combined senile diabetic cataract surgery and intravitreal lucentis injection on diabetic macular edema[J]. Chin J Pract Ophthalmol, 2014, 32(5):560-563.
[7] 刘会娟,宋艳萍,陈中山,等. 玻璃体腔注射雷珠单抗与玻璃体腔注射雷珠单抗联合光动力疗法治疗息肉样脉络膜血管病变的视力预后比较[J]. 中华眼底病杂志,2014, 30(3):249-252. LIU Huijuan, SONG Yanping, CHEN Zhongshan, et al. Comparison of visual outcomes between intravitreal ranibizumab injection combined with or without photodynamic therapy for polypoidal choroidal vasculopathy[J]. Chi J Ocul Fund Dis, 2014, 30(3):249-252.
[8] Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation[J]. Retina, 2008, 28(3):465-472.
[9] Kocabora MS, Yilmazli C, Taskapili M, et al. Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone[J]. Clin Ophthalmol, 2008, 2(1):167-171.
[10] Evoy KE, Abel SR. Ranibizumab: the first vascular endothelial growthfactor inhibitor approved for the treatment of diabetic macular edema[J]. Ann Pharmacother, 2013, 47(6):811-818.
[1] 朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[2] 孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[3] 朱云龙,王平,高萌. 误诊为中浆及视网膜炎的后巩膜炎1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 99-105.
[4] 丁术梁,王超凡,刘建亮. 眼内液检测指导精准治疗急性视网膜坏死1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 114-117.
[5] 沈嘉琪,李潇飒,毕燕龙,张敬法. 人工智能在DME筛查、诊断和预后中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 153-159.
[6] 鲍莹,刘志高,姜鹏飞,崔文轩,郑晓霞,杨梦瑶,司明威,王玉,王红. 康柏西普治疗糖尿病合并CRVO-ME高反射点的临床观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 55-60.
[7] 常威威,焦万珍,崔艳艳,赵杰,刘兆强,赵博军. 糖尿病性黄斑缺血的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 130-136.
[8] 周静琳,李金香,曾琦. 577 nm阈值下微脉冲激光联合抗VEGF药物治疗难治性糖尿病性黄斑水肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 18-25.
[9] 何静,雷春燕,张美霞. 糖化血红蛋白变异指数与糖尿病视网膜病变严重程度的相关性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 34-40.
[10] 顾冉冉,李凤娇,焦万珍,崔艳艳,赵博军. 卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 46-50.
[11] 张陶然,王薇,李明铭,黄映湘. IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 68-71.
[12] 韩克阳,于贝贝,赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131.
[13] 刘建波,张环. 超声乳化联合玻璃体腔药物注射治疗白内障合并糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 99-104.
[14] 周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[15] 靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发